Stock Markets May 6, 2026 02:11 AM

Ottobock posts 4.4% Q1 core sales increase, reiterates 2026 targets

Company reports margin expansion and confirms goals for 2026 and medium-term 2029 outlook

By Caleb Monroe

Ottobock reported core sales of €378 million in Q1 2026, a 4.4% increase from the prior year period, and confirmed its full-year guidance. Underlying core EBITDA rose 11.8% to €84.3 million and the underlying core EBITDA margin improved to 22.3%. The company maintained its 2026 sales growth and margin targets and reiterated its medium-term targets for 2029.

Ottobock posts 4.4% Q1 core sales increase, reiterates 2026 targets

Key Points

  • Core sales rose to €378 million in Q1 2026, a 4.4% increase from €362.6 million a year earlier; organic core growth was 5.1%. (Sectors impacted: healthcare, medical devices)
  • Underlying core EBITDA increased 11.8% to €84.3 million and the EBITDA margin improved to 22.3%, attributed to product mix, procurement initiatives, operating leverage and administrative cost discipline. (Markets impacted: corporate profitability and investor outlook)
  • Regional performance diverged: EMEA and APAC sales grew 8.1% and 8.3% respectively, while Americas revenue declined 9.8% with organic growth of negative 1.1%, influenced by order patterns and USD foreign exchange effects. (Markets impacted: regional sales dynamics and FX-sensitive reporting)

Ottobock SE & Co. KGaA released its first quarter 2026 financials on Wednesday, showing a 4.4% increase in core sales versus the same quarter a year earlier and reaffirming its full-year outlook.

Core revenue for the quarter reached €378 million, up from €362.6 million in Q1 of the prior year. On an organic basis, core growth was reported at 5.1%.

Segment performance

The B2C segment expanded by 6.1% overall, with organic growth of 4.7%. Management cited the acquisitions of patient care businesses Matton and Northern Prosthetics as supporting factors for B2C momentum during the quarter.

The B2B segment advanced by 3.0%, and showed stronger organic underlying growth of 5.5%. The company highlighted demand strength in prosthetics and neuro-orthotics offerings, naming products such as Genium X4, Kenevo and C-Brace as drivers in that channel.

Profitability and margins

Underlying core EBITDA increased 11.8% year-on-year to €84.3 million, up from €75.5 million in the comparable quarter. The underlying core EBITDA margin rose to 22.3% from 20.8% the previous year. Ottobock attributed the margin improvement to product mix effects, procurement initiatives, operating leverage and cost discipline within administrative functions.

Regional revenue trends

By region, sales were up in EMEA by 8.1% and in APAC by 8.3%. Revenues in the Americas declined by 9.8%, with organic growth in that region reported as negative 1.1%. The company pointed to a strong comparison base in Q1 2025, temporarily weaker order intake from a large client and the impact of USD foreign exchange movements as the reasons for the Americas shortfall.

Outlook

Ottobock confirmed its 2026 guidance, expecting core business sales growth of between 5% and 8% and projecting an underlying core EBITDA margin above 26.5% for the year. The company also left unchanged its medium-term objectives through 2029, targeting organic growth of 7% to 9% and an underlying core EBITDA margin in the 29% to 30% range.


Contextual summary

The quarter combined modest top-line expansion with stronger profitability metrics, driven by a mix of acquisitions, product mix and internal cost measures. Regional performance was uneven, with double-digit declines in the Americas offset by solid growth in EMEA and APAC.

Risks

  • Americas revenue decline of 9.8% and negative 1.1% organic growth indicate exposure to volatile order patterns, including temporarily weaker orders from a large client, which could affect near-term performance. (Impacted: healthcare and medical device customers in the Americas)
  • USD foreign exchange effects contributed to lower Americas revenues, highlighting currency risk in reported results when a significant portion of sales or costs are exposed to USD movements. (Impacted: financial reporting and investor expectations)
  • Margin improvements were attributed to factors such as product mix, procurement initiatives and operating leverage; these drivers must be sustained for margins to remain elevated. Changes in any of these areas could alter profitability trends. (Impacted: corporate margins and operational planning)

More from Stock Markets

SCOR posts better-than-expected Q1 results but faces steep premium declines at renewals May 6, 2026 Sampo Oyj Posts Q1 EPS Above Forecast on Strong Underwriting and Cost Gains May 6, 2026 ZEAL Network Posts Modest Billings Rise, Confirms 2026 Targets After Soft Jackpot Period May 6, 2026 Australian Stocks Close Higher as Metals, Materials and Financials Lead Gains May 6, 2026 Watchdog Warns Private Credit’s Bank and Asset Manager Links Could Amplify Systemic Strain May 6, 2026